JMP Securities Reaffirms Market Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “market outperform” rating reaffirmed by research analysts at JMP Securities in a note issued to investors on Thursday, Benzinga reports. They currently have a $23.00 price objective on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Vigil Neuroscience in a report on Wednesday, March 27th.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL traded down $0.03 during trading hours on Thursday, reaching $2.89. The stock had a trading volume of 22,124 shares, compared to its average volume of 100,458. Vigil Neuroscience has a 1 year low of $2.53 and a 1 year high of $11.11. The firm’s 50 day moving average is $3.17 and its 200-day moving average is $4.04. The stock has a market capitalization of $106.58 million, a price-to-earnings ratio of -1.35 and a beta of 1.77.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Strs Ohio acquired a new position in shares of Vigil Neuroscience in the 4th quarter valued at $27,000. Royal Bank of Canada acquired a new stake in Vigil Neuroscience during the 2nd quarter worth $33,000. California State Teachers Retirement System acquired a new stake in Vigil Neuroscience during the 2nd quarter worth $50,000. Wells Fargo & Company MN boosted its stake in Vigil Neuroscience by 6,988.4% during the 2nd quarter. Wells Fargo & Company MN now owns 6,096 shares of the company’s stock worth $57,000 after purchasing an additional 6,010 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in Vigil Neuroscience during the 2nd quarter worth $86,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.